Toronto Dominion Bank Has $8.90 Million Position in The Clorox Company (NYSE:CLX)

Toronto Dominion Bank decreased its stake in The Clorox Company (NYSE:CLX - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,767 shares of the company's stock after selling 10,977 shares during the quarter. Toronto Dominion Bank's holdings in Clorox were worth $8,895,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CLX. California Public Employees Retirement System increased its stake in shares of Clorox by 1.3% during the 4th quarter. California Public Employees Retirement System now owns 565,810 shares of the company's stock worth $91,893,000 after purchasing an additional 6,987 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Clorox by 14.0% during the 4th quarter. Deutsche Bank AG now owns 654,198 shares of the company's stock worth $106,248,000 after purchasing an additional 80,189 shares during the last quarter. Apollon Wealth Management LLC increased its stake in shares of Clorox by 119.6% during the 4th quarter. Apollon Wealth Management LLC now owns 3,364 shares of the company's stock worth $546,000 after purchasing an additional 1,832 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Clorox by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 4,074 shares of the company's stock worth $662,000 after purchasing an additional 646 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Clorox by 49.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 370,880 shares of the company's stock worth $60,235,000 after purchasing an additional 121,979 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Stock Performance

NYSE CLX traded down $1.66 during midday trading on Monday, hitting $130.23. The company had a trading volume of 1,406,696 shares, compared to its average volume of 1,342,194. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The stock has a market cap of $16.05 billion, a price-to-earnings ratio of 35.58, a P/E/G ratio of 2.62 and a beta of 0.60. The firm has a fifty day simple moving average of $138.04 and a two-hundred day simple moving average of $150.78. The Clorox Company has a fifty-two week low of $129.19 and a fifty-two week high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.71 earnings per share. Equities analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the firm's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the transaction, the director now owns 4,000 shares in the company, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.57% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Morgan Stanley dropped their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company dropped their price target on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Citigroup dropped their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research note on Monday, April 14th. UBS Group lowered their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Finally, Barclays lowered their target price on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, Clorox presently has a consensus rating of "Hold" and an average target price of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.